{"id":"W3108435873","doi":"10.1016/j.annonc.2020.10.088","title":"68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Internal medicine; Pembrolizumab; Carboplatin; Induction chemotherapy; Phases of clinical research; Chemotherapy; Cancer; Immunotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001123746,0.001771778,0.002159738,0.000364573,0.0003691458,0.001237186,0.0008867152,0.001436332,0.01194211],"category_scores_gemma":[0.0009090481,0.0007508966,0.001480217,0.0003885405,0.001008707,0.001252105,0.000414644,0.004500656,0.002027768],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008305839,"about_ca_system_score_gemma":0.001219864,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001100972,"about_ca_topic_score_gemma":0.002957415,"domain_scores_codex":[0.999656,0.0001482936,0.00001797813,0.00007465514,0.00002346169,0.0000796003],"domain_scores_gemma":[0.9995553,0.00008789728,0.00008462009,0.0000307255,0.00002258274,0.0002188186],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9473948,0.01369397,0.0006688956,0.0007514903,0.0009250776,0.00003627476,0.00005047628,0.000436631,0.006406549,0.0001913591,0.001659813,0.02778466],"study_design_scores_gemma":[0.9209001,0.07557258,0.001461178,0.00002457219,0.0003946566,0.00002882905,0.00002074701,0.0003134999,0.0003558401,0.0001145174,0.0008002543,0.00001319384],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816377,0.004262646,0.0009005667,0.00137693,0.0008006785,0.004415756,0.002301662,0.0002649777,0.004039166],"genre_scores_gemma":[0.9783177,0.003495628,0.002156953,0.001941916,0.000405378,0.004521756,0.00215665,0.00005855857,0.006945413],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01194211,"threshold_uncertainty_score":0.03995037,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1168465376839712,"score_gpt":0.4061263004334042,"score_spread":0.289279762749433,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}